Newsroom
Find everything you need for reporting on Teva: press releases, media kits, leadership information, and direct contacts for our communications team.
Press releases
UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease
Teva to Host R&D Day on Wednesday, November 11 in New York City
Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia
Media assets
Our Stories
Understanding Schizophrenia: The Human Impact, the Clinical Challenges and the Importance of Stability in Care
Teva in Q2 2026: Our transformation at a glance
Teva in Q1 2026: Our transformation at a glance
4 Things You Might Not Know About Our 2025 Healthy Future Report
Sustaining Teva’s Generics Powerhouse in the Acceleration Phase
Step Up Innovation
Pivot to Growth: The Acceleration Phase
Delivering on Growth Engines
Teva in 2025: Innovation drives third consecutive year of growth
Supporting Healthier Communities
Meet Our Leadership Team
Richard Francis
President and Chief Executive Officer, Member of the Board of Directors
Richard Daniell
Executive Vice President, European Commercial
Christine Fox
Executive Vice President, US Commercial, Head of Innovative Franchise
Dr. Eric A. Hughes
Executive Vice President, Global R&D and Chief Medical Officer
Placid Jover
Executive Vice President, Chief Human Resources Officer
Eli Kalif
Executive Vice President, Chief Financial Officer (CFO)
Evan Lippman
Executive Vice President, Business Development
Mark Sabag
Executive Vice President, International Markets Commercial
Matthew Shields
Executive Vice President, Teva Global Operations
Nir Baron
Senior Vice President, Chief Internal Auditor
Kathleen Veit
Senior Vice President, Global Compliance & Ethics Officer